Summary of Key Points
The Phase III clinical trial of the mRNA cancer vaccine developed in collaboration between Moderna and Merck Sharp & Dohme (targeting the prevention of melanoma recurrence after surgery) has been successful. This is the first positive result of its kind globally, which has directly driven Moderna’s stock price to rise by 14% and had a positive impact on the vaccine sectors in both the A-share and Hong Kong stock markets (for example, CanSino’s A-share stock soared by 20%). Domestic companies such as CanSino have quickly joined in the research and development efforts. However, this vaccine currently has a narrow range of indications (only melanoma) and is relatively expensive; domestic research and development is still in its early stages, so it will take some time before it becomes widely available to ordinary patients.
Detailed Analysis
1. Why is the stock market “crazy” about Moderna?
This breakthrough is milestone-worthy—the first mRNA cancer treatment vaccine to successfully complete Phase III clinical trials. Analysts describe this as a “Normandy moment,” indicating a shift in the vaccine industry from focusing on disease prevention (such as COVID-19 vaccines) to treating tumors, a market with significant potential. Investors have responded enthusiastically: Moderna’s stock price increased by 14%, and domestic vaccine stocks (such as CanSino and Wantai Biological) also saw significant gains. Even unrelated pharmaceutical stocks (such as Hansoh Pharmaceutical) have benefited from the market’s optimism about the future prospects in this field.
2. What makes mRNA cancer vaccines so impressive?
Unlike chemotherapy and radiotherapy, which can be highly destructive to healthy cells, mRNA vaccines offer a more targeted approach:
- They identify unique mutations in the patient’s tumor (each tumor has different mutations);
- They customize mRNA vaccines to help the immune system recognize these mutations;
- The immune system then targets the mutated cancer cells, achieving a “one-person, one-drug” approach.
This trial, specifically for patients after melanoma surgery, has shown effectiveness in reducing the risk of recurrence, which is why this breakthrough has received so much attention.
3. Rapid action from domestic companies
Seeing Moderna’s success, domestic companies have quickly moved forward. CanSino’s subsidiary has partnered with Hangzhou Depushi Biology to develop personalized mRNA cancer vaccines. The partnership focuses on digestive system tumors and rare cancers, with a collaborative approach from research and development to commercialization, aiming to target the global market. This demonstrates that domestic companies are already taking steps to secure a position in this emerging field.
4. When will ordinary patients be able to use these vaccines?
There are several challenges to overcome before widespread use:
- Narrow range of indications: The vaccine is only effective for melanoma, which affects approximately 8,800 patients in China each year. Common cancers (such as lung and stomach cancer) have not yet been tested;
- High cost: Personalized production is expensive, making them more costly than traditional cancer treatments (such as antibody drugs), although still cheaper than cell therapy. The price is a key factor in their adoption;
- Early stage of domestic research and development: Domestic mRNA cancer vaccines are still in the early clinical stages, lacking mature data and requiring improvements in production processes.
Conservatively, it will take at least 3–5 years before ordinary patients can use these vaccines.
5. Future prospects and challenges
- Prospects: mRNA technology can be applied beyond cancer vaccines, extending to areas such as protein replacement therapy and in vivo CAR-T therapy.
- Challenges:
- Clinical validation: Not all mRNA products will successfully pass Phase III trials;
- Precision delivery: Ensuring that mRNA reaches the target cells accurately is a critical technical hurdle;
- Scaling up production: How can personalized vaccines be produced at scale to reduce costs? Small companies will need to collaborate with larger companies for funding and technical support.
In summary, mRNA cancer treatment represents a promising field with a long way to go.